LORAZEPAM Drug Interactions
Also known as: LORAZEPAM
Lorazepam is a prescription medication used to help manage anxiety disorders and provide short-term relief from anxiety symptoms. It works by calming the brain and nerves, which can help reduce feelings of worry and tension.LORAZEPAM has 12 documented drug interactions in our database, including 3 contraindicated, 9 major, 0 moderate, and 0 minor interactions.
3
Contraindicated
9
Major
0
Moderate
0
Minor
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. Psychomotor impairment and an increased risk of falls are also common.
Mechanism
Morphine, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Lorazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors. The co-administration of these two CNS depressants leads to additive or synergistic depression of the CNS, particularly affecting respiratory drive.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse outcomes, as highlighted by an FDA Black Box Warning. If co-prescription is absolutely necessary and no alternatives are available, use the lowest effective doses and shortest possible duration, monitor patients closely for respiratory depression and sedation, and counsel them on the risks. Naloxone should be readily available for opioid overdose reversal.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, unresponsiveness, and difficulty arousing.
Mechanism
Both tramadol, an opioid analgesic, and lorazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly on the respiratory drive and level of consciousness, by enhancing GABAergic neurotransmission and opioid receptor agonism, respectively.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the FDA Black Box Warning. If co-administration is absolutely necessary and no alternatives exist, use the lowest effective doses for the shortest possible duration, closely monitor patients for respiratory depression and sedation, and educate patients and caregivers on the risks. Naloxone should be readily available.
Concomitant use can lead to severe and potentially fatal respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, bradycardia, hypotension, and miosis. The risk is heightened in opioid-naïve individuals, elderly patients, or those with underlying respiratory compromise.
Mechanism
Oxymorphone, a mu-opioid receptor agonist, and lorazepam, a gamma-aminobutyric acid (GABA)-A receptor positive allosteric modulator, both cause central nervous system (CNS) depression. Their co-administration leads to additive and synergistic CNS depressant effects, primarily by enhancing the inhibitory neurotransmission in the brainstem respiratory centers and other CNS areas. This leads to profound depression of ventilatory drive and reduced arousal.
Clinical Management
Concomitant use of opioids and benzodiazepines is contraindicated due to the high risk of severe adverse outcomes. If co-administration is unavoidable and no alternative treatment options are adequate, prescribers must limit dosages and duration to the minimum necessary and monitor patients closely for signs of respiratory depression and sedation. Naloxone should be readily available, and patients/caregivers must be educated on the risks and symptoms.
The primary clinical effects include profound sedation, respiratory depression, coma, and potentially death. Patients may exhibit reduced respiratory rate, shallow breathing, hypoxemia, and decreased level of consciousness. Other effects can include hypotension, bradycardia, and psychomotor impairment.
Mechanism
Buprenorphine, a partial opioid agonist, and lorazepam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Their co-administration leads to an additive and synergistic depression of the CNS, primarily by enhancing gamma-aminobutyric acid (GABA) activity (benzodiazepines) and opioid receptor agonism (buprenorphine). This combined effect significantly impairs respiratory drive and consciousness.
Clinical Management
Co-prescription of buprenorphine and lorazepam should generally be avoided due to the high risk of severe adverse outcomes, as highlighted by the FDA Black Box Warning. If co-administration is deemed absolutely necessary and no alternatives exist, it must be done with extreme caution, initiating with the lowest effective doses of both medications and titrating slowly while closely monitoring for signs of respiratory depression and sedation. Patients and caregivers must be educated about the risks and symptoms of overdose.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. These effects can be life-threatening if not promptly recognized and managed.
Mechanism
Fentanyl, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Lorazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors. The co-administration of these CNS depressants results in synergistic depression of respiratory drive and CNS activity.
Clinical Management
Avoid concomitant use of fentanyl and lorazepam whenever possible. If co-administration is unavoidable, use the lowest effective doses and shortest possible duration, and closely monitor patients for signs of respiratory depression and sedation. Ensure naloxone is readily available, and educate patients and caregivers about the risks and symptoms requiring immediate medical attention.
The combination significantly increases the risk of severe respiratory depression, which can lead to hypoxemia, apnea, and death. Patients may experience profound sedation, somnolence, dizziness, and impaired psychomotor function. Other serious effects include coma and hypotension.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS), leading to dose-dependent CNS depression, including respiratory depression and sedation. Lorazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, also causing CNS depression, sedation, and respiratory depression. The concurrent use of these two classes of drugs results in an additive and synergistic CNS depressant effect, profoundly increasing the risk of severe adverse outcomes.
Clinical Management
Co-prescription of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse events. If co-administration is absolutely necessary, it should be done with extreme caution, using the lowest effective doses for the shortest possible duration, and only if alternative treatments are inadequate. Patients and caregivers must be educated about the risks, including signs of respiratory depression and sedation, and instructed to seek immediate medical attention if these occur. Close monitoring for respiratory depression and altered mental status is crucial.
Concomitant use of oxycodone and lorazepam can lead to profound sedation, respiratory depression, coma, and death. This interaction significantly increases the risk of life-threatening adverse effects due to central nervous system (CNS) depression.
Mechanism
Both oxycodone (an opioid) and lorazepam (a benzodiazepine) are CNS depressants. Their co-administration results in an additive depressant effect on the CNS, particularly on respiratory drive and consciousness.
Clinical Management
Avoid concomitant use whenever possible. If co-prescription is unavoidable, use the lowest effective doses for the shortest duration, monitor patients closely for signs of respiratory depression and sedation, and counsel patients and caregivers on these risks.
The co-administration of codeine and lorazepam can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, apnea, and hypotension. These effects can be life-threatening and require immediate medical intervention.
Mechanism
Codeine is an opioid analgesic that primarily acts as a mu-opioid receptor agonist, leading to central nervous system (CNS) depression, including respiratory depression. Lorazepam is a benzodiazepine that enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in further CNS depression. The combined CNS depressant effects are synergistic, significantly increasing the risk of adverse outcomes.
Clinical Management
Avoid concomitant use of codeine and lorazepam whenever possible. If co-prescription is unavoidable, use the lowest effective doses and for the shortest duration necessary, carefully titrating and monitoring for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms of CNS depression and respiratory depression, advising them to seek immediate medical attention if these occur.
The concurrent use of methadone and lorazepam significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, and difficulty arousing. Other effects include dizziness, confusion, psychomotor impairment, and hypotension.
Mechanism
Both methadone, an opioid agonist, and lorazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive and synergistic depressant effect on the CNS, particularly on the respiratory drive and level of consciousness. This occurs through their respective actions on opioid receptors and GABA-A receptors, leading to enhanced inhibitory neurotransmission.
Clinical Management
Avoid concomitant prescribing of methadone and lorazepam whenever possible. If co-prescription is unavoidable, use the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks, and provide naloxone if appropriate. Consider non-benzodiazepine alternatives for anxiety or insomnia.
The concurrent use of hydromorphone and lorazepam significantly increases the risk of severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may exhibit decreased level of consciousness, bradycardia, pinpoint pupils, and hypoventilation. The FDA has issued a Black Box Warning highlighting these life-threatening risks.
Mechanism
Hydromorphone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia, sedation, and respiratory depression. Lorazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS activity.
Clinical Management
Avoid concomitant use of hydromorphone and lorazepam whenever possible. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of CNS depression, and consider prescribing naloxone for at-risk patients.
Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, bradycardia, hypotension, and hypoxemia. This interaction can also impair psychomotor function, increasing the risk of falls and accidents.
Mechanism
Both tapentadol (an opioid analgesic with norepinephrine reuptake inhibition) and lorazepam (a benzodiazepine) are central nervous system (CNS) depressants. Tapentadol's opioid activity primarily agonizes mu-opioid receptors, while lorazepam enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. The additive CNS depressant effects of these two drug classes lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Avoid concomitant use of tapentadol and lorazepam whenever possible due to the high risk of severe adverse outcomes, as highlighted by an FDA Black Box Warning. If co-prescription is absolutely necessary, use the lowest effective doses for the shortest possible duration, and closely monitor patients for signs of respiratory depression, sedation, and hypotension. Educate patients and caregivers about the risks and symptoms, and consider prescribing naloxone if appropriate.
Concomitant use of hydrocodone (an opioid) and lorazepam (a benzodiazepine) can lead to profound sedation, severe respiratory depression, coma, and death. This combination significantly increases the risk of life-threatening central nervous system depression.
Mechanism
Both hydrocodone and lorazepam cause central nervous system (CNS) depression. Hydrocodone acts on opioid receptors, while lorazepam enhances GABAergic activity. Their combined effects are additive, leading to synergistic CNS and respiratory depression.
Clinical Management
Avoid concomitant use if possible. If unavoidable, use the lowest effective doses for the shortest duration, closely monitor for respiratory depression and sedation, and educate patients/caregivers on warning signs. Consider naloxone availability.
For complete prescribing information:
View full LORAZEPAM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.